

CURRICULUM VITAE

October 10, 2002

NAME: RICHARD H. HAUBRICH, MD
Associate Adjunct Professor of Medicine
UCSD Antiviral Research Center
150 W. Washington Street, Suite 100
San Diego, CA 92103

**DATE &
PLACE OF
BIRTH:**

EDUCATION:

1979	BA in Chemistry, Occidental College, Los Angeles, CA
1983	MD, USC School of Medicine, Los Angeles, CA
1983-84	Intern, Mercy Hospital & Medical Center, San Diego, CA
1984-86	Resident, Mercy Hospital & Medical Center, San Diego, CA
1986-87	Chief Resident, Mercy Hospital & Medical Center, San Diego, CA
1987-90	Fellow, University of Massachusetts Medical Center, Worcester, MA

HONORS and AWARDS:

Medical School 1982 AOA

Post Graduate 1990 Maxwell Finland Young Investigators Award

APPOINTMENTS:

1987	Instructor in Medicine, Department of Medicine, University of California, San Diego
1988	Instructor in Medicine, Department of Medicine, University of Massachusetts Medical Center
1990	Assistant Professor of Medicine, Department of Medicine, University of Massachusetts Medical Center

- 1991 Assistant Clinical Professor of Medicine, Department of Medicine, Division of Infectious Diseases, University of California, San Diego
- 1998 Associate Adjunct Professor of Medicine, Department of Medicine, Division of Infectious Diseases, University of California, San Diego

BOARD CERTIFICATION:

- 1987 American Board of Internal Medicine
- 1990 American Board of Internal Medicine Subspecialty Examination – Infectious Disease

LICENSURE:

- 1984 California – Certificate # _____, Expiration 07/31/2002
- 1987 Massachusetts

FELLOWSHIP/SCHOLARSHIPS:

State Graduate Fellowship (medical school), 1979 - 1983

RESEARCH ACTIVITIES:

- Oct 1987 - Jun 1990 Immune Enhancement of HIV Infection using HIV Antibody Positive Serum.
- Jul 1990 - Jul 1991 ACTG Clinical Trials.
- 1991 - Current UCSD ACTG and CCTG Trials include cryptococcal meningitis, combination antiretroviral therapy, fungal susceptibility studies, HIV-1 protease inhibitor therapy, and clinical strategy trials of HIV technologies.

PUBLICATIONS:

1. Swordlow N, Haubrich R. Aggressive treatment of a patient with the acquired immune deficiency syndrome (letter). *Annals of Internal Medicine* 107(4):597 1987.

2. **Haubrich RH**, Keroack N. Pneumococcal crepitant cellulitis caused by a bronchocutaneous fistula. *Chest* 101:566-567 1992.
3. **Haubrich RH**, Takeda A, Koff W, Smith G, Ennis F. Studies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 mediated by F_c receptors using serum from recipients of a recombinant gp160 experimental HIV- 1 vaccine. *Journal of Infectious Diseases* 165:545-548, 1992.
4. **Haubrich RH**, Bozzette SA. Fluconazole. In: *Therapeutic Drugs:Supplement 1*, Ed. CT Dollery, Churchill Livingstone, 1992.
5. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G, (**Haubrich RH**). A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. *New England Journal of Medicine* 327:581-587, 1992.
6. **Haubrich RH**, Haghighat D, Bozzette SA, Tilles J, McCutchan JA, California Collaborative Treatment Group. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. *Journal of Infectious Diseases*;170:238-242, 1994.
7. Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly WG, He W, Phillips L, Craven D, van der Horst C, Feinberg J, for the NIAID AIDS Clinical Trial Group (**Haubrich RH**). A randomized trial of three anti-pneumocystis agents in patients with advanced human immunodeficiency virus infection. *New England Journal of Medicine* 332:693-699, 1995.
8. Powderly WG, Finkelstein DM, Feinberg J, Frame P, He W, van der Horst C, Koletar SL, Eyster ME, Carey J, Waskin H, Hooton TM, Hyslop N, Spector SA, Bozzette SA, for the NIAID AIDS Clinical Trial Group, (**Haubrich RH**). A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. *New England Journal of Medicine* 332:700-705, 1995.
9. **Haubrich R**, McCutchan JA, Holdredge R, Heiner L, Merritt J, Merchant B. An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V) (HIV-1III Benv/rev retroviral vector) in HIV-1-infected subjects. *Human Gene Therapy*, 6(7):941-955, 1995.
10. Studies of Ocular Complications of AIDS Research Group in Collaboration with AIDS Clinical Trials Group, (**Haubrich RH**). Antiviral effects of foscarnet and ganciclovir therapy on human immunodeficiency virus p24 antigen in patients with AIDS and cytomegalovirus retinitis. *Journal of Infectious Diseases* 172:613-21, 1995.

11. **Haubrich RH**, Flexner C, Lederman MM, Hirsch M, Pettinelli CP, Ginsberg R, Lietman P, Hamzeh FM, Spector SA, Richman DD and the AIDS Clinical Trials Group 213 Team. A randomized trial of the activity and safety of Ro 24-7429 (TAT antagonist) versus nucleoside for human immunodeficiency virus infection. *Journal of Infectious Diseases* 172 2:1246-1252, 1995.
12. **Haubrich RH**, Warner J, Anderson CG, Merritt J, Jacobsen C, McCutchan JA. Cytotoxic T- lymphocyte augmentation using an HIV-1 *Env/Rev* encoding retroviral vector (HIV-IT[V]) as Therapy for HIV. *Gene Therapy*;2:599-600, 1995.
13. Warner JF, Jolly D, Mento S, Galpin J, **Haubrich RH**, Merritt J. DNA Vaccines: Retroviral vectors for HIV immunotherapy. *Annals of the New York Academy of Sciences* 772:105-116, 1995.
14. Witt MD, Lewis RJ, Larsen RA, Milefchik EN, Leal MA, **Haubrich RH**, Richie JA, Edwards JE, Ghanoum MA. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing. *Clinical Infectious Diseases* 22:322-328, 1996.
15. Torriani FJ, Behling CA, McCutchan JA, **Haubrich RH**, Havlir DV. Disseminated *Mycobacterium avium* complex: Correlation between blood and tissue burden. *Journal of Infectious Diseases* 173:942-949, 1996.
16. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, **Haubrich RH**, Henry WK, Lederman MM, Phair RT, NIU M, Hirsch MS, Merigan TC, for the AIDS Clinical Trials Group Study 175 Study Team. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. *New England Journal of Medicine* 335:1081-1090, 1996.
17. **Haubrich RH**, Warner J, Anderson CG, Peters G, Merritt J, Jacobsen C, McCutchan JA. Immunotherapy for HIV-1 using an HIV-1 *Env/Rev* encoding retroviral vectors [HIV-IT(V)]. In: *Gene Delivery Systems*. Published in OECD World Conference Proceedings: 323-334, 1996.
18. **Haubrich R**, Saag M, Management of HIV-associated fungal diseases (pp.10-14). *Improving the Management of HIV Disease*, International AIDS Society-USA, 4(5): 10-14, February 1997.
19. Fischl MA, Richman DD, Flexner C, Para MF, **Haubrich R**, Karim A, Yeramian P, Holden-Wiltse J, Meehan PM. Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV Protease Inhibitor SC-52151. *Journal of Acquired Immune Deficiency and Human Retrovirology* 15:28-34, 1997.
20. **Haubrich R**. Advances in the diagnosis and monitoring of HIV disease. *HIV Update: Guidelines and Beyond*. Published in Conference Proceedings, 3-9, December 8, 1997.

21. **Haubrich R**, Lalezari J, Follansbee SE, Gill M J, Hirsch M, Richman D, Mildvan D, Burger HU, Beattie D, Donatacci L, Salgo MP, and the NV14256 Study Team. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. *Antiviral Therapy* 3: 33-42, 1998.
22. Metzgar D, Field D, **Haubrich R**, Wills C. Sequence analysis of a compound coding-region microsatellite in *Candida albicans* resolves homoplasies and provides a high-resolution tool for genotyping. *Fems Immunology and Medical Microbiology* 20 (2): 103-109, 1998.
23. Havlir DV, **Haubrich R**, Hwang J, Dunne MW, Currier J, Forthal D, Torriani F, Richman DD, McCutchan JA. Human immunodeficiency virus Replication in AIDS Patients with *Mycobacterium avium* Complex Bacteremia: a Case Control Study. *Journal of Infectious Diseases* 177: 595-599, 1998.
24. El-Sadr WM, Murphy RL, Yurik TM, Luskin-Hawk R, Cheung TW, Balfour HH Jr, Eng R, Hooton TM, Kerkering TM, Schultz M, Van Der Horst C, Hafner R, for the Community Program for Clinical Research on AIDS, and for the AIDS Clinical Trials Group (**Haubrich R**). Atovaquone compared with dapsone for the prevention of *Pneumocystis Carinii* pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. *The New England Journal of Medicine* 339(26): 1889-1895, 1998.
25. Metzgar D, van Belkum A, Field D, **Haubrich R**, Wills C. Random amplification of polymorphic DNA and microsatellite genotyping of pre- and posttreatment isolates of *Candida* spp. from human immunodeficiency virus-infected patients on different fluconazole regimens. *Journal of Clinical Microbiology* 36 (8): 2308-2313, 1998.
26. Morales AJ, **Haubrich RH**, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100mg daily dose of dehydroepiandrosterone (DHEA) on circulation sex steroids, body composition and muscle strength in age-advanced men and women. *Clinical Endocrinology* 49(4): 421-432, 1998.
27. **Haubrich R**, Richman D. Nevirapine, didanosine, and zidovudine for patients with HIV: The INCAS trial. (Letter) *Journal of the American Medical Association* 281 (2): 130-131, 1999.
28. Revicki DA, Swartz C, Wu AW, **Haubrich R**, Collier AC. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm³. *Antiviral Therapy* 4:35-44, 1999.
29. **Haubrich RH**, Havlir D. Nelfinavir. *AIDS Therapy*, Ed. Dolin, Masur, Seag, Churchill Livingstone 177-187, 1999.

30. **Haubrich RH**, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, Johnson D, Dube MP, Hwang JY, McCutchan JA, and the California Collaborative Treatment Group. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. *AIDS* 13 (9): 1099-1107, 1999.
31. Forthal DN, Landucci G, **Haubrich R**, Keenan B, Kuppermann BD, Tilles JG, and Kaplan J. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. *Journal of Infectious Diseases* 180:1338-1341, 1999.
32. **Haubrich R**, Thompson M, Schooley R, Lang W, Stein A, Sereni D, van der Ende ME, Antunes F, Richman D, Pagano G, Kahl L, Fetter A, Brown DJ, Clumeck N, and the Amprenavir PROAB2002 Study Team. A Phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. *AIDS* 13 (17) 2411-2420, 1999.
33. Sha BE, Johnson VA, Kendall MA, **Haubrich R**, Nokta M, Lamb K., Zackin RA, Nail CD, and Currier JS. Absence of virological changes after acute febrile illnesses in two patients with undetectable pre-illness plasma HIV-1RNA levels *AIDS*; 14 (6):746-748, 2000.
34. Günthard HF, Wong JD, Spina C.A., Ignacio C, Kwok S, Christopherson C, Hwang J, **Haubrich R**, Havlir D, and Richman DD. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. *Journal of Infectious Diseases*; 181:522-531, 2000.
35. Gulick RM, Hu XJ, Fisman SA, Fletcher CV, **Haubrich R**, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, and Katzenstein D. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. *Journal of Infectious Diseases* 182:1375-1384, 2000.
36. Moss NE, Lemp G, Blumenthal R, Goldsmith MA, **Haubrich R**, Kahn JO. From the cell to the community: AIDS research in California. *Western Journal of Medicine*, 173:119-124, 2000.
37. Lederman MM, McKinnis R, Kelleher D, Cutrell A, Mellors J, Neisler M, Cooney E, Haas DW, **Haubrich R**, Stanford J, Horton J, Landay A, Spreen W. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. *AIDS*, 14(17):2635-2642, 2000.
38. **Haubrich RH**. Structured treatment interruptions: Review of current data. *Topics in HIV Medicine*, 8(7):9-13, 2000.

39. Fletcher CV, Acosta EP, Cheng HL, **Haubrich R**, Fischl M, Raasch R, Mills C, Hu XJ, Katzenstein D, Remmel RP, Gulick RM, for the ACTG 884 Protocol Team. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. *AIDS*, 14(16):2495-2501, 2000.
40. Katzenstein DA, Hughes M, Albrecht M, Hammer S, Para M, Murphy R, Valdez H, **Haubrich R**, Liou S. Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group. *AIDS Research and Human Retroviruses*, 16(11):1031-1037, 2000.
41. Demeter L, **Haubrich R**. Phenotypic and genotypic resistance assays: Methodology, reliability, and interpretations. *Journal of Acquired Immune Deficiency Syndromes*, 26(Suppl 1):S3-S9, 2001.
42. **Haubrich R**, Demeter L. Clinical utility of resistance testing: Retrospective and prospective data supporting use and current recommendations. *Journal of Acquired Immune Deficiency Syndromes*, 26(Suppl 1):S51-S59, 2001.
43. Kemper CA, Witt MA, Keiser PH, Dubé MP, Forthal DN, Leibowitz M, Smith DS, Rigby A, Hellmann NS, Lie YS, Leedom J, Richman D, McCutchan JA, **Haubrich R**, and the California Collaborative Treatment Group #575 Team. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. *AIDS*, 15(5):609-615, 2001.
44. **Haubrich RH**, Currier JS, Forthal DN, Beall G, Kemper CA, Johnson D, Dubé MP, Hwang J, Leedom JM, Tilles J, McCutchan JA, and the California Collaborative Treatment Group. A randomized study of the utility of HIV RNA measurement for the management of antiretroviral therapy in HIV-infected patients with less than 500 CD4 cells/mm³. *Clinical Infectious Diseases*, 33:1060-1068, 2001.
45. McMahon D, Lederman M, Haas DW, **Haubrich RH**, Stanford J, Cooney E, Horton J, Kelleher D, Ross L, Cutrell A, Lee D, Spreen W, Mellows JW. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naïve HIV-1-infected adults. *Antiviral Therapy*, 6(2):105-114, 2001.
46. Schooley RT, Clumeck N, **Haubrich R**, Thompson M, Danner SA, van Der Ende ME, Sereni D, Antunes F, Blake D, Myers RE, Tisdale M, Millard J, Mustafa N, Nacci P. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir. *Antiviral Therapy*, 6:133-140, 2001.
47. Becker S, Fisher A, Flexner C, Gerber JG, **Haubrich R**, Kashuba AD, Luber AD, Piscitelli SC. Pharmacokinetic parameters of protease inhibitors and the C_{min}/IC₅₀ ratio: call to consensus. *Journal of Acquired Immune Deficiency Syndromes*, 27(2):210-1, 2001.

48. Eron JJ, **Haubrich R**, Lang W, Pagano G, Millard J, Wolfram J, Snowden W, Pedneault L, Tisdale M. A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir. *Journal of Acquired Immune Deficiency Syndromes*, 26(5):458-61, 2001.
49. Sadler BM, Gillotin C, Lou Y, Eron JJ, Lang W, **Haubrich R**, Stein DS. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. *Antimicrob Agents Chemother*, 45(12):3663-8, 2001.
50. Back D, Gatti G, Fletcher C, Garaffo R, **Haubrich R**, Hoetelmans R, Kurowski M, Lubner A, Merry C, Perno CF. Therapeutic drug monitoring in HIV infection: current status and future directions. *AIDS*, 16(Suppl 1):S5-S37, 2002.
51. Swindells S, Evans S, Zackin R, Goldman M, **Haubrich R**, Filler SG, Balfour JR HH; AIDS Clinical Trial Group 722 Study Team. Predictive Value of HIV-1 Viral Load on Risk for Opportunistic Infection. *J Acquir Immune Deficiency Syndromes* 30(2):154-158, June 2002.
52. Mathews WC, Cole J, Ballard C, Colwell B, **Haubrich R**, Barber E, Lew T. Early Adoption of HIV-1 Resistance Testing in the San Diego County Ryan White CARE Act Program: Predictors and Outcomes. *AIDS Patient Care and STDs*, 16(7): 337-48, 2002.
53. Gulick R, Hu J, Fiscus S, Fletcher C, **Haubrich R**, Cheng H, Acosta E, Lagakos S, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D, for the AIDS Clinical Trials Group Protocol 359 Team. Durability of Response to Treatment among Antiretroviral-Experienced Subjects: 48-Week Results from AIDS Clinical Trials Group Protocol 359. *The Journal of Infectious Diseases* 2002;186:626-33
54. **Haubrich RH**, Kemper CA, Hellmann N, Keiser P, Witt M, Forthal D, Leedom J, Leibowitz M, Whitcomb J, Richman D, McCutchan JA and the California Collaborative Treatment Group. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. *AIDS* 2002; 16:F33-F40 (Fast Track).

PUBLISHED ABSTRACTS:

55. **Haubrich RH**, McCutchan JA, Caralli V, Spector SA, Jacobsen C, Kang C, Merritt J. Safety and immunogenicity of a monoclonal anti-idiotypic antibody (3C9) plus SAF-m adjuvant for HIV-infected patients. *Journal of Cellular Biochemistry*, Keystone Symposia, Suppl 17E:79, 1993.
56. **Haubrich R**, Burger HU, Beattie D, Donatucci L, Salgo MP, and the NV14256 Study Team. UCSD, San Diego, CA, USA. Saquinavir plus zalcitabine vs saquinavir or zalcitabine monotherapy in HIV-infected patients discontinuing or intolerant to zidovudine: Results of a randomized, double blind trial. *AIDS*, 10(Suppl 1,2):S17, 1996.

57. **Haubrich R**, Kemper C, Witt M, Keiser P, Dubé M, Forthal D, Currier J, Seefried E, Rigby A, Richman D, Hellmann N, Heilek G, Lie Y, McCutchan JA, & the CCTG. Differences in protease inhibitor (PI) phenotypic susceptibility after failure of the first PI-containing regimen. *Antiviral Therapy*, 4(Suppl 1):55, 2000. [80]
58. **Haubrich R**, Whitcomb J, Keiser P, Kemper C, Witt M, Dubé M, Forthal D, Leibowitz M, Hwang J, Rigby A, Hellmann N, McCutchan JA, Richman D, and the CCTG. Non-nucleoside reverse transcriptase inhibitor viral hypersensitivity is common and improves short-term virological response. *Antiviral Therapy*, 5(Suppl 3):69, 2000. [87]

ABSTRACTS:

Presented at the 7th International Conference on AIDS/2nd STD World Congress, Florence, Italy, 1991, and published in the abstracts of the meeting.

1. **Haubrich RH**, Takeda A, Koff W, Smith C, Ennis FA. Lack of FCR-mediated enhancement in sera from recipients of RGP160 experimental HIV vaccine. [MA 1327]

Presented at the 8th International Conference on AIDS/3rd STD World Congress, Amsterdam, the Netherlands, 1992, and published in the abstracts of the meeting.

2. **Haubrich RH**, Haghighat D, Bozzette SA, Tilles J, McCutchan JA, and the CCTG. Pilot study of the treatment of Cryptococcal meningitis with 800 mg of fluconazole. [PoB 3186]

Presented at the Second International Congress on Biological Response Modifiers, San Diego, California, 1993, and published in the abstracts of the meeting.

3. **Haubrich RH**, McCutchan JA, Caralli V, Spector SA, Jacobsen C, Kang C, Merritt J. Safety and immunogenicity of a monoclonal anti-idiotypic antibody (3C9) plus SAF-m adjuvant for HIV-infected patients. [30]

Presented at the 9th International Conference on AIDS/4th STD World Congress, Berlin, Germany, 1993, and published in the abstracts of the meeting.

4. Kang CY, **Haubrich RH**, Jacobsen C, Caralli V, McCutchan JA, Merritt J. Controlled phase I clinical study of a monoclonal anti-idiotypic antibody (3C9) in HIV-infected patients. [WS-B28-3]
5. **Haubrich RH** and the ACTG 213 Team. A randomized study of safety, tolerance, pharmacokinetics, and activity of oral Ro 24-7429 (TAT antagonist) in patients with HIV infection. [WS-B26-5]

6. Milefchik E, Leal M, **Haubrich RH**, Haghighat D, Bozzette S, Larsen R. High dose fluconazole with and without flucytosine for AIDS associated cryptococcal meningitis. [WS-B12-5]

Presented at the First National Conference on Human Retroviruses and Related Infections, Washington DC, December 1993, and published in the abstracts of the meeting.

7. Spina C, Hurtubise P, Weinhold K, Frame P, Waskin H, **Haubrich RH**, Bozzette S. The use of CD8 subset phenotypes as prognostic indicators of disease progression in patients with advanced HIV infection receiving long-term antiretroviral therapy. [436]

Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 1994, and published in the abstracts of the meeting.

8. **Haubrich RH**, Ashburn W, Thomas D, Blair D, Murray P, Vanderwal H, Bozzette S. Pertechnegas (PG) for the diagnosis of HIV-associated *Pneumocystis Carinii* pneumonia (PCP). [D45]

Presented at the 2nd National Conference on Human Retroviruses and Related Infections, Washington DC, January 29-February 2, 1995 and published in the abstracts of the meeting.

9. Torriani F, Behling C, McCutchan JA, **Haubrich RH**, Keays L, Havlir D. Disseminated *Mycobacterium avium* complex (MAC): Correlation between blood cultures and tissue burden in AIDS patients.[115]
10. Fischl MA, Richman DD, Flexner C, Meehan P, Para MF, **Haubrich RH**, Cook J, Wood K, Karim A. Phase I study for two formulations and dose schedules of SC- 52151, a protease inhibitor. [186]
11. **Haubrich RH**, Flexner C, Lederman M, Hirsch M, Herman S, Studlack M, Wang J, Dreyer K, Richman DD. Quantitative HIV RNA measured by reverse transcription PCR (RT PCR) as a marker of activity of antiviral therapy. [337]
12. **Haubrich RH**, Hirsch M, Flexner C, Lederman M, Ginsberg R, Richman DD. Effect of antiretroviral discontinuation (AD) and reintroduction on markers of HIV infection. [381]
13. Anderson CG, Lynn A, Johnson P, McDonald D, Apodaca J, Ronlov G, **Haubrich RH**, McCutchan JA, Warner JF. Use of heterologous matched targets to monitor HIV-specific CTL responses in HIV-seropositive subjects. [LB8]

Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995, and published in the abstracts of the meeting.

14. **Haubrich RH**, Warner J, Anderson C, Holdredge R, Peters G, Baud C, Merritt J, Merchant B, Jacobsen C, McCutchan JA and the CCTG. Phase I study of an HIV_{III}B *Env/Rev* encoding retroviral vector [HIV-IT(V)] in HIV seropositive patients with CD4 200. [175]
15. Lee D, **Haubrich RH**, Mathews C, McCutchan JA and the CCTG. Catheter-related bacteremia/ fungemia (CRB) in AIDS patients with permanent catheters; microbiology, risk factors and outcomes.[1251]

Presented at the 3rd Conference on Retroviruses and Opportunistic Infections, Washington DC, January 28-February 1, 1996.

16. **Haubrich RH**, Havlir D, Torriani F, Parenti D, Forthal D, Witt M, Bozzette S, Dunne M, McCutchan JA. The effect of daily (D) versus weekly (W) fluconazole (FZ) prophylaxis on susceptibility of oral *Candida* isolates in HIV-infected patients. [567]

Presented at the 11th International Conference on AIDS, Vancouver, WA, July 7-12, 1996, and published in the abstracts of the meeting.

17. **Haubrich RH**, Field D, Eggert L, Metzger D, McCutchan JA, Willis C and the California Collaborative Treatment Group, University of California, San Diego, CA, USA. The use of microsatellites to distinguish strains of *Candida albicans* colonizing HIV-infected patients on fluconazole. [Tu.B.2198]
18. Billyard, Elizabeth, **Haubrich R**, Nunomura K, Garduno F, Ueding K, Mimms L, Debra Durand, McCutchan A, The California Collaborative Treatment Group, The HIV Neurobenavious Research Center, Gen-Probe Incorporated, San Diego, CA, USA, UCSD, San Diego, CA, USA. Use of a single tube quantitative RNA assay to characterize a population of HIV-infected patients. [We.B.3384]
19. Lalezari J, **Haubrich R**, Burger HU, Beattie D, Donatucci L, Salgo MP and the NV14256 Study Team. Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase™, SQV) plus HIVID (Zalcitabine, ddC). [Lb.B.6033]

Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997, and published in the abstracts of the meeting.

20. Milefchik E, Leal M, **Haubrich R**, Bozzette B, Tilles J, Leedom J, McCutchan JA, Larsen RA of the California Collaborative Treatment Group. A Phase II dose escalation trial of high dose fluconazole with and without flucytosine for AIDS associated Cyptococcal meningitis. [5]

21. Anderson CG, Lynn A, McDonald D, Alfonso J, **Haubrich R**, McCutchan JA, Jolly DJ, Warner JF. Comparison of MHC restriction elements of HIV-specific CTL activity in HIV-seropositive subjects. [108]
22. Havlir DV, **Haubrich R**, Hwang JH, Dunne M, Torriani F, Currier J, Forthal D, Bozzette SA, Richman DD, McCutchan JA, and the CCTG/MOPPS Team. Sequential HIV RNA levels in patients with disseminated *M. avium* complex (MAC): A case control study. [360]
23. Little S, **Haubrich R**, Hwang J, Stevens V, Yocum R, Hoff S, Looney D. Protease inhibitors are associated with favorable response to topical treatment of Kaposi's sarcoma. [702]

Presented at the 14th Annual UARP AIDS Investigators Meeting; San Francisco, CA, March 20th 1997.

24. **Haubrich R**, Little S, Weinrich J, Hwang J, McCutchan JA, and the California Collaborative Treatment Group (CCTG). Measures of patient adherence in CCTG 570: A trial of antiretroviral monitoring strategies
25. **Haubrich R**, McCutchan JA, Currier J, Forthal D, Beall G, Kemper C, Takamoto J, Hwang J, Ignosci J, Mai M. Baseline characteristics including HIV RNA and CD4 measures in CCTG 570.
26. Weinrich J, Little S, **Haubrich R**, Hwang J, McCutchan JA, and the California Collaborative Treatment Group (CCTG). Personality and psychological predictors of adherence: Patient self-reports versus physician provider estimates. [R96-SD-1502]

Presented at the 37th ICAAC (International Conference on Antimicrobial Agents and Chemotherapy). Toronto, Canada, September 28–October 1, 1997, and published in the abstracts of the meeting.

27. **Haubrich R**, Currier J, Forthal D, Beall G, Kemper C, Takamota J, Dube M, Ignosci J, Johnson D, Hwang J, McCutchan JA. Low rate of maximal suppression of HIV-1 RNA in a trial of RNA monitoring in clinical practice. [I-128b]

Presented at the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998, and published in the abstracts of the meeting.

28. Mellors M, Haas D, Horton J, **Haubrich R**, Stanford J, Cooney E, Donnenberg A, Neisler M, Kelleher D. Early T-lymphocyte responses to antiretroviral therapy with abacavir (1592) and HIV protease inhibitors (PIs). [364]
29. **Haubrich R**, Currier J, Forthal D, Beall G, Kemper C, Dube M, Ignosci J, Johnson D, Hwang J, McCutchan JA, and the California Collaborative Treatment Group. Utility of

HIV RNA measurements to monitor antiretroviral (ARV) therapy in patients with <500 CD4 cells/mm³. [513]

Presented at the 1st Annual Conference on AIDS Research in California and 15th Annual UARP Meeting. Los Angeles, CA. February 27, 1998.

30. **Haubrich RH**, Little S, Currier D, Forthal D, Beall G, Kemper C, Dube M, Johnson D, Rigby A, Hwang J, McCutchan JA and the California Collaborative Treatment Group. Improving treatment adherence in a plasma viremia trial. [R96-SD-1501]

Presented at the 12th World AIDS Conference. Geneva, Switzerland, June 28 - July 3, 1998, and published in the abstracts of the meeting.

31. Kelleher D, Mellors J, Lederman M, Haas D, Cooney E, Horton J, Stanford J, **Haubrich R**. Activity of abacavir (1592, ABC) combined with protease inhibitors (PI) in therapy naive patients. [12210]
32. Kelleher D, Lederman M, Mellors J, Haas D, Cooney E, Horton J, Stanford J, **Haubrich R**. Early and sustained changes in lymphocyte sub-populations during a bacavir (ABC) and PI therapy. [12213]
33. **Haubrich R**, Currier JS, Forthal D, Beall G, Kemper C, Dube M, McCutchan JA. Factors associated with successful ritonavir salvage therapy in an open trial of antiretroviral (ARV) therapy. [12318]
34. **Haubrich R**. Phase 2 study of amprenavir, a novel protease inhibitor, in combination with zidovudine.3TC. [12321]
35. **Haubrich R**, Hwang J, Ellis RJ, McCutchan JA, Heaton R, Bodrug S, Dose E. HIV-1 RNA as measured by the Gen-Probe TMA assay, predicts neurocognitive outcomes as well as progression to AIDS and death in HIV infected patients. [32195]
36. **Haubrich R**, Little S, Dube M, Forthal D, Beall G, Kemper C, Hwang J, McCutchan JA. Self reported treatment adherence and drug/alcohol use are associated with virologic outcomes in CCTG 570: A clinical strategy trial of HIV RNA antiretroviral (ARV) monitoring [32379].

Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31 - February 4, 1999, and published in the abstracts of the meeting.

37. Gunthard H, Wong J, Spina C, Ignacio C, Kwok S, Christopherson C, Wang J, **Haubrich R**, Havlir D, Richman DD. Impact of influenza vaccination (IFV) on HIV plasma RNA and patterns of immune response (IR) in patients (pts) on HAART. [337]
38. Acosta EP, Guick R, Katzenstein D, **Haubrich R**, Fischl M, Raasch R, Mills C, Pettinelli C, Rimmel RP, Fletcher CV. Pharmacokinetic (PK) evaluation of saquinavir soft gel

capsules (SQV)/ritonavir (RTV) or SQV/nelfinavir (NFV) in combination with delavirdine (DLV) and/or adefovir dipivoxil (ADV). [365]

39. Hwang J, **Haubrich R**, Currier J, Forthal D, Beall G, Kemper C, McCutchan J. Comparison of three statistical measures of HIV RNA suppression in a clinical strategy trial. [395]
40. Mellors J, Lederman M, Haas D, Horton J, **Haubrich R**, Stanford J, Cooney E, Lafon S, Kelleher D. Durable activity of ziagen (abacavir, ABC) combined with protease inhibitors (PI) in therapy naive adults. [625]

Presented at the Second International Workshop on Salvage Therapy for HIV Infection; Toronto, Canada, May 19-21, 1999, and published in the abstracts of the meeting.

41. Gulick RM, Katzenstein D, Hu J, Fiscus S, Fletcher CV, **Haubrich R**, Cheng H, Lagakos S, Acosta E, Swanstrom R, Mills C, Snyder S, Fischl M, Pettinelli C, for the ACTG 359 Team. Salvage therapy with saquinavir soft gel capsules in combination with ritonavir or nelfinavir and delavirdine, adefovir dipivoxil, or both: ACTG 359 [020].
42. **Haubrich R**, Kemper C, Beall G, Keiser P, Dube M, Forthal D, Currier J, Seefried E, Rigby A, Richman D, Hellmann N and the ViroLogic Clinical/Research Laboratory, McCutchan JA, and the CCTG. Differences in protease inhibitor (PI) phenotypic susceptibility after failure of the first PI-containing regimen [028].

Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26 – 29, 1999, and published in the abstracts of the meeting.

43. **Haubrich R**, Kemper C, Witt M, Keiser P, Dubé M, Forthal D, Currier J, Seefried E, Hwang J, McCutchan JA, Hellmann N, Heilek G, Kie Y, Richman D. Reproducibility of an HIV phenotype resistance assay in clinical practice. [417]
44. **Haubrich R**, Kemper C, Witt M, Keiser P, Dubé M, Forthal D, Currier J, Hwang J, Richman D, Hellmann N, Heilek G, Lie Y, McCutchan JA. Differences in protease inhibitor (PI) phenotypic susceptibility after failure of the first PI-containing regimen. [1167]

Presented at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30 – February 2, 2000, and published in the abstracts of the meeting.

45. Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, **Haubrich R**, Cheng H, Lagakos S, Acosta E, Swanstrom R, Mills C, Snyder M, Fischl M, Pettinelli C, Katzenstein D for the ACTG 359 Team. Salvage therapy with saquinavir SGC (SQV) in combination with ritonavir (RTV) or nelfinavir (NFV) plus delavirdine (DLV), adefovir dipivoxil (ADV), or both—ACTG 359. [235]

46. **Haubrich R**, Keiser P, Kemper C, Witt M, Dubé M, Forthal D, Leibowitz M, Hwang J, Rigby A, McCutchan JA, Hellmann N, Richman DD, and the CCTG. Characterization of altered phenotypic antiretroviral (ARV) susceptibility to drugs in a failing regimen. [753]
47. Mathews C, **Haubrich R**, Barber E, Havlir D. Patterns and prognostic implications of prior antiretroviral therapy (ART) at UCSD Owen Clinic: 1996–1999. [762]

Presented at the 13th International AIDS Conference, Durban, South Africa, July 9–14, 2000, and published in the abstracts of the meeting.

48. **Haubrich R**, Keiser P, Kemper C, Witt M, Dubé M, Forthal D, Leibowitz M, Hwang J, Rigby A, McCutchan JA, Hellmann N, Richman D, and the CCTG. Factors associated with reduced susceptibility to drugs in the current failing antiretroviral (ARV) regimen. [TuPeB3288]
49. Hawkins T, Grossman D, **Haubrich R**. CNS side effects of EFV may persist in patients thought to tolerate the drug. [WePpB3177]

Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, September 17–20, 2000, and published in the abstracts of the meeting.

50. Huang W, Parkin NT, Lie YS, Wrin T, **Haubrich R**, Deeks S, Hellmann NS, Petropoulos CJ, Whitcomb JM. A novel HIV-1 RT mutation (M320L) confers NNRTI resistance and dose-dependent stimulation of replication. [480]
51. **Haubrich R**, Whitcomb J, Keiser P, Kemper C, Witt M, Johnson D, Forthal D, Leibowitz M, Hwang J, Rigby A, Hellmann N, Richman D, McCutchan JA. Non-nucleoside reverse transcriptase inhibitor (NNRTI) hypersusceptibility (HS) is common and improves short-term virologic response. [481]

Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4 – 8, 2001, and published in the abstracts of the meeting.

52. Gulick RM, Hu XJ, Fiscus S, Fletcher CV, **Haubrich R**, Cheng H, Lagakos S, Acosta E, Swanstrom R, Mills C, Snyder S, Fischl M, Pettinelli C, Katzenstein D, for the ACTG 359 Team. Durability of salvage therapy with saquinavir SGC (SQV) in combination with ritonavir (RTV) or nelfinavir (NFV) plus delavirdine (DLV), adefovir dipovoxil (ADV), or both—ACTG 359: 48-week final [338].
53. Kemper C, **Haubrich R**, Frank I, Buscarino C, McCutchan J, Deresinski S, and the California Collaborative Treatment Group. The safety and immunogenicity of hepatitis A vaccine [Havrix (HVX)] in HIV+ patients: A double-blind, randomized, placebo-controlled trial [558].

Presented at the 5th International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, Arizona, June 4-8, 2001, and published in *Antiviral Therapy* 6 (Suppl 1), 2001.

54. **Haubrich R**, Keiser P, Kemper C, Witt M, Leedom J, Forthal D, Leibowitz M, Hwang J, Seefried E, McCutchan JA, Hellmann N, Richman D, and the CCTG Study Team. CCTG 575: A randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy [Abstract 80, p. 63].
55. Keiser P, Evans L, Skiest D, **Haubrich R**, O'Brien WA. Genotypic predictors of non-nucleoside reverse transcriptase inhibitor hypersusceptibility and clinical response to efavirenz in patients with hypersusceptibility [Abstract 107, p. 80].

Presented at the 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 8-11, 2001, and published in the abstracts of the meeting.

56. **Haubrich R**, Keiser P, Kemper C, Witt M, Leedom J, Forthal D, Hellmann N. CCTG 575: A Randomized, Prospective Study of Phenotype Testing (PHENO) Versus Standard of Care (SOC) for Patients Failing Antiretroviral Therapy (ARV) [127].
57. Keiser P, Evans L, **Haubrich R**, O'Brien W, Skiest D. Genotypic Predictors of Efavirenz Hypersusceptibility and Clinical Response to Efavirenz in Patients with Efavirenz Hypersusceptibility [601].

Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28, 2002, and published in abstracts of the meeting.

58. Fletcher CV, Cheng H, Fiscus SA, Swanstrom R, Hellmann NS, **Haubrich R**, Katzenstein D, and Gulick R, for the ACTG 359 Team. The Inhibitory Quotient (IQ) for Saquinavir (SQV) Predicts Virologic Response to Salvage Therapy [129].
59. Swanstrom R, Katzenstein D, Hellmann NS, Fiscus SA, Petch L, Cheng H, **Haubrich R**, Gulick R. Resistance Mutations in Subjects with Non-Nucleoside Analogue (NNRTI) Hypersusceptibility – Results from ACTG 359 [567-T].
60. Swanstrom R, Cheng H, Hellmann NS, Katzenstein D, Bosch RJ, Fiscus SA, **Haubrich R**, Gulick R. Alternative Phenotypic Sensitivity Scores and Outcome Measures Increase Detection of the Impact of Drug Resistance on Response to Salvage Therapy – Results from ACTG 359 [592-T].
61. Dorfman D, Chu A, **Haubrich R**, Naseer M, Petersen C, Schmeidler J, Simpson D. Neuropsychiatric Complications of Efavirenz (EFV): Results of a Randomized Prospective Comparison with Nelfinavir (NFV) in Antiretroviral (ARV)-Naïve Patients [719-T].
62. Brundage RC, Acosta E, **Haubrich R**, Katzenstein D, Gulick R, Fletcher CV. Quantitation of Sex Differences and Drug Interactions: Pharmacologic Studies of Saquinavir (SQV) in ACTG 359 [779-W].